BioSpace News Archive

LIXTE Biotechnology Holdings, Inc., a clinical stage pharmaceutical company, announced a collaboration with Roche and the Netherlands Cancer Institute to conduct a new clinical trial in immune therapy unresponsive metastatic colon cancer.

LIXTE Biotechnology Holdings, Inc., a clinical stage pharmaceutical company, announced a collaboration with Roche and the Netherlands Cancer Institute to conduct a new clinical trial in immune therapy unresponsive metastatic colon cancer.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced voting results for its 2024 annual general meeting (the Meeting) of shareholders held on June 14, 2024.

Vancouver, British Columbia--(Newsfile Corp. - June 14, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic” or the “Company”) - Further to the Company’s news release of June 6, 2024, the Company is pleased to announce that...

BrainStorm Cell Therapeutics Inc. is focused on developing autologous mesenchymal stem cell therapies for the treatment of neurodegenerative diseases – BCLI’s primary target is the fatal amyotrophic lateral sclerosis.

Vancouver, British Columbia--(Newsfile Corp. - June 14, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the “Company” or “PreveCeutical”) is providing an update with respect to the Management Cease Trade Order (“MCTO”) issued by the...

Researchers at Children’s Hospital of Philadelphia (CHOP) announced the discovery of a novel immune-based biomarker that could pave the way for potential lifesaving early detection of high-grade ovarian cancer (HGOC).

Toronto, Ontario--(Newsfile Corp. - June 14, 2024) - Justera Health Ltd. (CSE: VTAL) (OTC Pink: SCRSF) (“Justera” or the “Company”) is pleased to announce that it has entered into a non-binding Letter of Intent (the “LOI”) on June 13, 2024, to acquire 100% of the issued and...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it has submitted an amendment to its Emergency Use Authorization to the U.S. Food and Drug Administration (FDA) for its updated JN.1 COVID-19 vaccine (NVX-CoV2705) for individuals aged 12 and older.

Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present encouraging new data from the ongoing Phase 1/2 ATALANTA-1 study of CD19 CAR-T candidate, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) at the annual European Hematology Association (EHA) 2024 Hybrid Congress.